menu search

Fda clears lyell immunopharma' lyl132 trial for solid tumors

The FDA has cleared Lyell Immunopharma Inc's (NASDAQ: LYEL) Investigational New Drug (IND) application to initiate a Phase 1 trial for LYL132 in so...

January 24, 2022, 12:39 pm

Fda clears lyell immunopharma' lyl132 trial for solid tumors

The FDA has cleared Lyell Immunopharma Inc's (NASDAQ: LYEL) Investigational New Drug (IND) application to initiate a Phase 1 trial for LYL132 in so...

January 24, 2022, 12:39 pm

Merck's gefapixant for chronic cough slapped with fda complete response letter

The FDA has issued a Complete Response Letter (CRL) to Merck Co & Inc's (NYSE: MRK) gefapixant for refractory chronic cough (RCC) or unexplained c...

January 24, 2022, 7:14 am

Merck's gefapixant for chronic cough slapped with fda complete response letter

The FDA has issued a Complete Response Letter (CRL) to Merck Co & Inc's (NYSE: MRK) gefapixant for refractory chronic cough (RCC) or unexplained c...

January 24, 2022, 7:14 am

Merck's gefapixant for chronic cough slapped with fda complete response letter

The FDA has issued a Complete Response Letter (CRL) to Merck Co & Inc's (NYSE: MRK) gefapixant for refractory chronic cough (RCC) or unexplained c...

January 24, 2022, 7:14 am

Aslan pharma kickstarts mid-stage atopic dermatitis trial, data expected in 2023

ASLAN Pharmaceuticals Ltd (NASDAQ: ASLN) has screened the first patient in its Phase 2b dose-ranging study of eblasakimab (ASLAN004) in adults with...

January 21, 2022, 6:36 am

Aslan pharma kickstarts mid-stage atopic dermatitis trial, data expected in 2023

ASLAN Pharmaceuticals Ltd (NASDAQ: ASLN) has screened the first patient in its Phase 2b dose-ranging study of eblasakimab (ASLAN004) in adults with...

January 21, 2022, 6:36 am

Aslan pharma kickstarts mid-stage atopic dermatitis trial, data expected in 2023

ASLAN Pharmaceuticals Ltd (NASDAQ: ASLN) has screened the first patient in its Phase 2b dose-ranging study of eblasakimab (ASLAN004) in adults with...

January 21, 2022, 6:36 am

Celyad oncology announces january 2022 conference schedule

MONT-SAINT-GUIBERT, Belgium, Dec. 22, 2021 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company fo...

December 22, 2021, 1:00 am

Celyad oncology announces january 2022 conference schedule

MONT-SAINT-GUIBERT, Belgium, Dec. 22, 2021 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company fo...

December 22, 2021, 1:00 am

Celyad oncology announces january 2022 conference schedule

MONT-SAINT-GUIBERT, Belgium, Dec. 22, 2021 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company fo...

December 22, 2021, 1:00 am

Cullinan oncology posts updated data for cln-081 in nsclc egfr exon 20 patients

Cullinan Oncology Inc (NASDAQ: CGEM) reported updated data from its ongoing Phase 1/2a trial of CLN-081 in non-small cell lung cancer (NSCLC) patie...

December 16, 2021, 1:04 pm

Cullinan oncology posts updated data for cln-081 in nsclc egfr exon 20 patients

Cullinan Oncology Inc (NASDAQ: CGEM) reported updated data from its ongoing Phase 1/2a trial of CLN-081 in non-small cell lung cancer (NSCLC) patie...

December 16, 2021, 1:04 pm

Cullinan oncology posts updated data for cln-081 in nsclc egfr exon 20 patients

Cullinan Oncology Inc (NASDAQ: CGEM) reported updated data from its ongoing Phase 1/2a trial of CLN-081 in non-small cell lung cancer (NSCLC) patie...

December 16, 2021, 1:04 pm

Should you buy chemocentryx stock as shares spike 70% on avacopan approval?

On Friday, ChemoCentryx Inc. (NASDAQ:CCXI) shares spiked nearly 70% after announcing the Food and Drug Administration (FDA) had approved avacopan for ...

October 8, 2021, 4:30 pm

Should you buy chemocentryx stock as shares spike 70% on avacopan approval?

On Friday, ChemoCentryx Inc. (NASDAQ:CCXI) shares spiked nearly 70% after announcing the Food and Drug Administration (FDA) had approved avacopan for ...

October 8, 2021, 4:30 pm

Should you buy chemocentryx stock as shares spike 70% on avacopan approval?

On Friday, ChemoCentryx Inc. (NASDAQ:CCXI) shares spiked nearly 70% after announcing the Food and Drug Administration (FDA) had approved avacopan for ...

October 8, 2021, 4:30 pm


Search within

Pages Search Results: